Similar companies
Related EMIS Industry Reports
Visen Pharmaceuticals is engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The company was established in 2018 and is headquartered in Suzhou City, Jiangsu Province.
Headquarters
Room 3-108, 3rd Floor, Building B, Hengtai Ideal Innovation Building, No. 69 Jiuzhang Road, Suzhou, China
Suzhou; Jiangsu;
Contact Details: Purchase the Visen Pharmaceuticals (维升药业) report to view the information.
Website: http://www.visenpharma.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS service
To view more information, Request a demonstration of the EMIS service